Samsung Bioepis’ ‘Benepali’ & ‘Flixabi’ showing significant sales growths

Biogen, a European seller of Samsung Bioepis’ ‘Benepali’ and ‘Flixabi,’ has announced their performance(4^th quarter performance in Europe) on the 25^th(local time).

According to the performance, ‘Benepali(Enbrel biosimilar’) and ‘F;oxabi(Remicade biosimilar),’ anti-TNF alpha antibodies developed by Samsung Bioepis, recorded USD 379.8 million European sales(approximately KRW 417.8 billion) in 20...